Market-Cap of 28 Mio US$ is wayyyy Undervalued !!!!

UPCOMING MILESTONES

Complete recruiting for modified REGENESIS Phase IIb clinical stroke trial end of Q1 10

Top-line read of modified REGENESIS Phase IIb stroke trial data
end of Q2 10

Initiate and enrol patients in a Phase IIa clinical study for traumatic brain injury H1 10


Initiate clinical Proof-of-Concept study for multiple sclerosis 2010

RPTR = Top Pick 2010 !!!!!

Raptor Pharma (RPTP)

Market Cap : 43 Mio$
Cash : 10,5 Mio$
Price : 1,90 $


Upcoming Milestones...

WntTideTM (Breast Cancer) Preclinical (ongoing) data to publish Q4 2009

DR Cysteamine Non-Alcoholic Steatohepatitis ("NASH") Phase IIa (ongoing, open IND), data Q4 09

DR Cysteamine Nephropathic Cystinosis (“Cystinosis”) Phase IIa (ongoing, open IND) Orphan Drug Designation, IIb ongoing, Phase III Q1 2010

DR Cysteamine Huntington’s Disease ("HD") Phase II (planned Q1 2010) Orphan Drug Designation


Raptor Pharmaceutical Corp. (RPTP)

Target Price: $6.56

Raptor announced positive findings from the completed treatment phase of its open-label Phase 2a clinical trial of delayed-release cysteamine bitartrate ("DR Cysteamine") in adolescent patients with non-alcoholic steatohepatitis ("NASH"), a progressive form of liver disease believed to affect 2% to 5% of the U.S. population.
the completion of the initial six-month treatment phase, the study achieved the primary endpoint: mean blood levels of alanine aminotransferase ("ALT"), a common biomarker for NASH, were reduced by over 50%. Additionally, over half of the study participants had achieved normalized ALT levels by the end of the treatment phase. There are no currently approved drug therapies for NASH. These interim results have established proof-of-concept and support further clinical development of DR Cysteamine in NASH.
The Company also announced that data from a clinical trial of NGX426, the Company's orally administered non-opioid, AMPA/kainate antagonist, will be presented at the 12th International Conference on the Mechanisms and Treatment of Neuropathic Pain, to be held November 20-21, 2009 in San Francisco. The objective of the single center, double-blind, randomized study conducted by Mark Wallace, M.D., Professor of Clinical Anesthesiology at the Center for Pain Medicine of the University of California at San Diego, was to demonstrate that the orally administered prodrug NGX426, maintains the analgesic effect previously shown for the active moiety tezampanel. Using a cross-over design, a total of 18 study subjects received single doses of 90 mg of NGX426, 150 mg of NGX426 or placebo in each of three treatment periods. Pain was induced by injecting 250 ug of capsaicin between layers of skin in the forearm at 30 minutes and 120 minutes after dosing. This is yet another valuable asset in Raptor’s clinical pipeline. The Company plans to continue to explore options with NGX426 in the treatment of pain, which potentially include spinning-out or partnering this program to ensure that shareholders receive the maximum value from this potentially groundbreaking drug.
In addition, Raptor will potentially have their cystinosis drug on the market in 1H 2011. The fact that Raptor is potentially 18 months away from producing revenues represents a significant opportunity for investors and why we believe Raptor’s share price will increase substantially from current levels. Raptor currently has a balanced pipeline of clinical and preclinical programs. The Company is currently involved in four Phase II clinical programs. The Company’s clinical trials address indications representing large markets worldwide: ALDH2 deficiency and NASH; along with Orphan Indications which typically have a shorter development cycle: cystinosis, and Huntington’s Disease. ALDH2 deficiency and Huntington’s Disease each represent potentially billion dollar markets.

http://blog.mdbpartners.com/2009/08/30/three-recent-biotechnology-activist-wins-by-carl-icahn/

Ticker


Company Name


# Shares

Held


% of Outstanding


Recent

Price


$ Value of Shares Held
BIIB Biogen Idec, Inc.

16,075,256


5.56%


$49.93


$802,637,532
AMLN Amylin Pharmaceuticals, Inc.

12,971,328


9.20%


$12.91


$167,459,844
REGN Regeneron Pharmaceuticals, Inc.

2,508,001


3.22%


$22.33


$56,003,662
ENZN Enzon Pharmaceuticals, Inc.

3,521,075


7.82%


$7.19


$25,316,529
ENDP Endo Pharmaceuticals Holdings, Inc.

1,129,126


0.97%


$22.74


$25,676,325
EXEL Exelixis, Inc.

2,357,110


2.20%


$5.71


$13,459,098
MEDX Medarex, Inc.

313,040


0.24%


$15.97


$4,999,249
ANX Adventrx Pharmaceuticals, Inc.

4,324,324


3.66%


$0.17


$722,162
EMIS Emisphere Technologies, Inc.

86,430


0.24%


$0.94


$81,244

Fantastic New for Puramed

Market Cap 11 Mio$

Great News ..Check it out !!!!
http://finance.yahoo.com/news/PuraMed-BioScience-Begins-to-pz-3559931568.html?x=0&.v=1

Great News ..Check it out !!!!
http://finance.yahoo.com/news/PuraMed-BioScience-Begins-to-pz-3559931568.html?x=0&.v=1

EMIS =Rally has begun ...

We could see 1 US$ today !!!!

Time to buy

EMIS = Another Top Pick 2010

Chart looks very bullish

http://seekingalpha.com/article/179100-a-window-of-opportunity-to-buy-emisphere

A Window of Opportunity to Buy Emisphere

When Emisphere's (EMIS) news release entitled "Emisphere Technologies Reports DMC Recommendation to Proceed with Phase 3 Clinical Trials with Oral Calcitonin for Osteoporosis and Osteoarthritis" hit the wires last week, it was the single biggest event in the company's history. If you weren't already totally up on the story the significance probably would have been lost on you. The Data Monitoring Committee based their recommendation to proceed upon "an assessment of safety and efficacy parameters."

Translation: that the drug is safe (should come as no surprise to anyone that read my previous articles) and that we are hitting our primary endpoints in both trials. This was absolutely huge news, which we greeted with open buy orders. It is my opinion that it is no longer a question of whether Oral Calcitonin will be approved for both indications or not; it is merely a question of timing, and the timing of approvals might be sooner than most are expecting.

Novartis (NVS) has been playing their cards close to their vest with the entire Oral Calcitonin program. In my opinion they are doing this because they know they have a huge winner on their hands and they want to keep the competition in the dark as long as possible; that is why we have yet to see any publication of data from the Calcitonin for Osteoarthritis Phase 2 trial that was completed almost 2 years ago.

I sincerely believe that when we start seeing some actual data from the Phase 2 trial people will be absolutely blown away by the results that will show significant widening of joint space width and a significant regrowth of cartilage. Novartis has said that they will wait for the completion of the US Osteoarthritis trial to file in the EU but I do not see why they would do this. I think that they will file in the EU in the early summer of 2010 and have approval in late 2010, which would mean commercial revenues much faster than people are anticipating.

The Osteoporosis trial also appears to be 2 full years ahead of the time-line spelled out on the clinicaltrials.gov website. We were not supposed to have our futility look until September 2011. Calcitonin is already a standard of care for Osteoporosis; we are just changing the delivery to oral so the shorter time-line would make more sense especially given the safety profile. I think that Novartis always had the option of going with a shorter study if the data were overwhelmingly good. I think that this is what is happening and that Novartis will be able to get FDA approval in late 2010 or early 2011; way ahead of schedule. This would mean commercial revenues from both Osteoporosis and Osteoarthritis start hitting in Q1 2011.

So if Oral Calcitonin is really going to get approved for both indications and it is going to happen a lot sooner than people expect then why is the fully diluted market cap of the company a mere $60 million?

There are two reasons. First, the secrecy and confidentiality of the Novartis partnership prevents Emisphere from clearly explaining the development of Oral Calcitonin. Investors must figure it out for themselves. Second, the last financing was managed very poorly and was very dilutive. There were two funds that bought a total of 5.2 million shares in the August financing and they got 100% warrant coverage. They appear to have been selling their shares and taking their risk capital off the table, keeping the warrants for profit. This would be carrying out a trading strategy rather than a fundamental strategy. They look at it and say we paid 70 cents for our investment so if we can sell our entire common stock position at an average of 70 cents or better we will have recouped all of our initial investment (or in this scenario even a little profit in addition) and we will still have the same amount of warrants as stock that we bought that are priced at 70 cents.

Therefore if the stock goes up we still make a killing on our warrants while already having taken the risk off the table. That is why the stock has not moved but I think that the sellers are getting down to tag ends. Get in now before the seller cleans up; I think this stock is going to be up substantially by the end of January(yes, next month) and it will still be dirt cheap as investors begin flocking to this opportunity.

EMIS = TOP PICk 2010

http://seekingalpha.com/article/179100-a-window-of-opportunity-to-buy-emisphere

A Window of Opportunity to Buy Emisphere

When Emisphere's (EMIS) news release entitled "Emisphere Technologies Reports DMC Recommendation to Proceed with Phase 3 Clinical Trials with Oral Calcitonin for Osteoporosis and Osteoarthritis" hit the wires last week, it was the single biggest event in the company's history. If you weren't already totally up on the story the significance probably would have been lost on you. The Data Monitoring Committee based their recommendation to proceed upon "an assessment of safety and efficacy parameters."

Translation: that the drug is safe (should come as no surprise to anyone that read my previous articles) and that we are hitting our primary endpoints in both trials. This was absolutely huge news, which we greeted with open buy orders. It is my opinion that it is no longer a question of whether Oral Calcitonin will be approved for both indications or not; it is merely a question of timing, and the timing of approvals might be sooner than most are expecting.

Novartis (NVS) has been playing their cards close to their vest with the entire Oral Calcitonin program. In my opinion they are doing this because they know they have a huge winner on their hands and they want to keep the competition in the dark as long as possible; that is why we have yet to see any publication of data from the Calcitonin for Osteoarthritis Phase 2 trial that was completed almost 2 years ago.

I sincerely believe that when we start seeing some actual data from the Phase 2 trial people will be absolutely blown away by the results that will show significant widening of joint space width and a significant regrowth of cartilage. Novartis has said that they will wait for the completion of the US Osteoarthritis trial to file in the EU but I do not see why they would do this. I think that they will file in the EU in the early summer of 2010 and have approval in late 2010, which would mean commercial revenues much faster than people are anticipating.

The Osteoporosis trial also appears to be 2 full years ahead of the time-line spelled out on the clinicaltrials.gov website. We were not supposed to have our futility look until September 2011. Calcitonin is already a standard of care for Osteoporosis; we are just changing the delivery to oral so the shorter time-line would make more sense especially given the safety profile. I think that Novartis always had the option of going with a shorter study if the data were overwhelmingly good. I think that this is what is happening and that Novartis will be able to get FDA approval in late 2010 or early 2011; way ahead of schedule. This would mean commercial revenues from both Osteoporosis and Osteoarthritis start hitting in Q1 2011.

So if Oral Calcitonin is really going to get approved for both indications and it is going to happen a lot sooner than people expect then why is the fully diluted market cap of the company a mere $60 million?

There are two reasons. First, the secrecy and confidentiality of the Novartis partnership prevents Emisphere from clearly explaining the development of Oral Calcitonin. Investors must figure it out for themselves. Second, the last financing was managed very poorly and was very dilutive. There were two funds that bought a total of 5.2 million shares in the August financing and they got 100% warrant coverage. They appear to have been selling their shares and taking their risk capital off the table, keeping the warrants for profit. This would be carrying out a trading strategy rather than a fundamental strategy. They look at it and say we paid 70 cents for our investment so if we can sell our entire common stock position at an average of 70 cents or better we will have recouped all of our initial investment (or in this scenario even a little profit in addition) and we will still have the same amount of warrants as stock that we bought that are priced at 70 cents.

Therefore if the stock goes up we still make a killing on our warrants while already having taken the risk off the table. That is why the stock has not moved but I think that the sellers are getting down to tag ends. Get in now before the seller cleans up; I think this stock is going to be up substantially by the end of January(yes, next month) and it will still be dirt cheap as investors begin flocking to this opportunity.

Market Cap of 8 Million US$ is a big Joke !!!!!!!!!!!!!!!

LipiGesic™ M

LipiGesic™ M provides acute relief from migraine headaches, and contains the herbs feverfew and ginger as principal ingredients. PuraMed believes that its specific formulation of these herbs for its migraine remedy is unique and proprietary, providing relief from these severe headaches in minutes. The Company believes it will capture a material segment of the huge migraine headache remedy market. We believe that Americans spend in excess of $6 billion annually on headache pain relievers, and that over half of sufferers of migraine headaches rely exclusively on non-prescription medications.

We believe that at least 30 million Americans suffer from chronic migraine headaches with over 20 million of them having “severe” migraine conditions. Thus migraine headaches constitute a severe and disabling condition for millions of people. We further believe that the economic burden alone to the U.S. economy is in excess of $20 billion annually.

LipiGesic™ M is effective, available as a non-prescription remedy, without any known side effects, and affordable compared to more expensive migraine drugs based on prescription chemical formulations.


LipiGesic™ PM

LipiGesic™ PM is a new class of non-prescription sleep aid without any known side effects, and contains a proprietary blend of natural ingredients including Valerian, St. John’s Wort, and Chamomile. We believe that the proprietary blend of these ingredients provides an effective remedy for insomnia and other sleep disorders. The sleep aid market features products based primarily on chemical antihistamines.

Accordingly, the LipiGesic™ PM product provides a wide open market opportunity for an effective, natural alternative to prescription medications, which are somewhat addictive and often cause withdrawal symptoms and other side effects. We have priced LipiGesic™ PM as a premium sleep aid product, which provides us with a projected gross margin of approximately 80%. This large margin should leave us substantial room for ample introductory promotion, product allowances and other incentives conducive to achieving rapid market penetration.

Similar to the migraine remedy market, the market for sleep aid products represents a very large segment of the overall healthcare products marketplace. We believe that over half of all adults in the U.S. suffer from sleep disorders, and that many of them experience persistent insomnia. The National Center on Sleep Disorders has reported that there are as many as 70 million problem sleepers in the U.S. with many of them suffering from chronic sleep disorders. We believe that insomnia is second only to pain as a healthcare complaint.

Future LipiGesic™ Products

We have completed development of additional non-prescription products, which we intend to launch commercially over the next couple years after establishing a solid market for our initial two products. These other PuraMed products include:

LipiGesic™ H – provides relief for common tension headaches which afflict a majority of American adults from time to time. This remedy provides headache relief features a unique proprietary formulation of St. John’s Wort and common aspirin.

LipiGesic™ Smoker’s Pal – provides relief from the symptoms associated with nicotine withdrawal with the added benefit of an appetite suppressant.

LipiGesic™ RLS – provides relief of problematic leg cramps associated with Restless Leg Syndrome affecting a large segment of the population in the U.S.

LipiGesic™ GI – provides relief of symptoms associated with nighttime reflux disorders.

LipiGesic™ CS – provides fast relief for canker sore outbreaks.

Market Cap of 8 Million US$ is a big Joke !!!!!!!!!!!!!!!

LipiGesic™ M

LipiGesic™ M provides acute relief from migraine headaches, and contains the herbs feverfew and ginger as principal ingredients. PuraMed believes that its specific formulation of these herbs for its migraine remedy is unique and proprietary, providing relief from these severe headaches in minutes. The Company believes it will capture a material segment of the huge migraine headache remedy market. We believe that Americans spend in excess of $6 billion annually on headache pain relievers, and that over half of sufferers of migraine headaches rely exclusively on non-prescription medications.

We believe that at least 30 million Americans suffer from chronic migraine headaches with over 20 million of them having “severe” migraine conditions. Thus migraine headaches constitute a severe and disabling condition for millions of people. We further believe that the economic burden alone to the U.S. economy is in excess of $20 billion annually.

LipiGesic™ M is effective, available as a non-prescription remedy, without any known side effects, and affordable compared to more expensive migraine drugs based on prescription chemical formulations.


LipiGesic™ PM

LipiGesic™ PM is a new class of non-prescription sleep aid without any known side effects, and contains a proprietary blend of natural ingredients including Valerian, St. John’s Wort, and Chamomile. We believe that the proprietary blend of these ingredients provides an effective remedy for insomnia and other sleep disorders. The sleep aid market features products based primarily on chemical antihistamines.

Accordingly, the LipiGesic™ PM product provides a wide open market opportunity for an effective, natural alternative to prescription medications, which are somewhat addictive and often cause withdrawal symptoms and other side effects. We have priced LipiGesic™ PM as a premium sleep aid product, which provides us with a projected gross margin of approximately 80%. This large margin should leave us substantial room for ample introductory promotion, product allowances and other incentives conducive to achieving rapid market penetration.

Similar to the migraine remedy market, the market for sleep aid products represents a very large segment of the overall healthcare products marketplace. We believe that over half of all adults in the U.S. suffer from sleep disorders, and that many of them experience persistent insomnia. The National Center on Sleep Disorders has reported that there are as many as 70 million problem sleepers in the U.S. with many of them suffering from chronic sleep disorders. We believe that insomnia is second only to pain as a healthcare complaint.

Future LipiGesic™ Products

We have completed development of additional non-prescription products, which we intend to launch commercially over the next couple years after establishing a solid market for our initial two products. These other PuraMed products include:

LipiGesic™ H – provides relief for common tension headaches which afflict a majority of American adults from time to time. This remedy provides headache relief features a unique proprietary formulation of St. John’s Wort and common aspirin.

LipiGesic™ Smoker’s Pal – provides relief from the symptoms associated with nicotine withdrawal with the added benefit of an appetite suppressant.

LipiGesic™ RLS – provides relief of problematic leg cramps associated with Restless Leg Syndrome affecting a large segment of the population in the U.S.

LipiGesic™ GI – provides relief of symptoms associated with nighttime reflux disorders.

LipiGesic™ CS – provides fast relief for canker sore outbreaks.

When introduced commercially, these other products will be packaged and branded much like the initial LipiGesic™ products, since we intend to devote substantial efforts and resources toward gaining a favorable and consistent brand and packaging for all PuraMed products to attempt to make them instantly recognizable on retail store shelves.

Break out is comingggggggggggggg !!!!!!!!

GLTA


IGXT.OB

Market Cap : 18 Mio$
Price : 0,56 $

Shares Out : 33 M

http://www.intelgenx.com/_assets/pdf/Rodman-Renshaw-Sept-2009.pdf

Filed NDA with U.S. Food and Drug Administration (FDA) - on April 3, 2009 the Company and Cary Pharmaceuticals filed a New Drug Application (NDA) under CFR 21 paragraph 505(b)(2) for the CPI-300 antidepressant. CPI-300 is a new strength of a leading antidepressant that will provide a more convenient dosing option to patients with major depressive disorder ("MDD").

The NDA has been formally accepted by the FDA for standard review. Pursuant to Prescription Drug User Fee Act (PDUFA) guidelines, IntelGenx expects the FDA will complete its review or otherwise respond to the NDA by February 6, 2010.

Break out is comingggggggggggggg

GLTA


IGXT.OB

Market Cap : 18 Mio$
Price : 0,56 $

Shares Out : 33 M

http://www.intelgenx.com/_assets/pdf/Rodman-Renshaw-Sept-2009.pdf

Filed NDA with U.S. Food and Drug Administration (FDA) - on April 3, 2009 the Company and Cary Pharmaceuticals filed a New Drug Application (NDA) under CFR 21 paragraph 505(b)(2) for the CPI-300 antidepressant. CPI-300 is a new strength of a leading antidepressant that will provide a more convenient dosing option to patients with major depressive disorder ("MDD").

The NDA has been formally accepted by the FDA for standard review. Pursuant to Prescription Drug User Fee Act (PDUFA) guidelines, IntelGenx expects the FDA will complete its review or otherwise respond to the NDA by February 6, 2010.

Upcoming Events ..2 Presentation in 2010

http://www.investorawareness.com/default.asp

Upcoming Events

PuraMed BioScience Financial Luncheon Presentation
- Tuesday, January 19, 2010
- 12:00 pm (event details)

PuraMed BioScience Financial Luncheon Presentation
- Wednesday, January 20, 2010
- 12:00 pm (event details)

The recent pullback in the stock price presents an attractive entry point ahead of several catalysts in 2010 !

GLTA


Puramed (PMBS.OB)

Market Cap: 7,7 Mio$
Price: 0,65 $

Shares Out : 11,99 M (8,6 M Shares held by Insider)
Float : 2,6 Million

Why Puramed Bioscience Inc. (PMBS.OB) Should Be On Your Radar

PuraMed Bioscience, Inc. is a pharmaceutical company focused on developing and marketing a line of new, non-prescription medicines. These products target major consumer health needs, including the treatment of headaches, insomnia, and general pain. The company aims launch its first retail products within six months, and then leverage that success to become a leader in the Over-the-Counter (OTC) medicine marketplace.

Although PuraMed Bioscience is entering into a competitive market, the company’s products promise to bring innovation to the industry, allowing for faster absorption into the blood stream, greater effectiveness, fewer side effects, and lower dosage requirements. The first three products the company plans to introduce include: LipiGesic M™ (for acute relief of migraine headaches), LipiGesic H™ (for acute relief of tension headaches) and LipiGesic PM™ (for insomnia).

PuraMed is already sufficiently funded via private funding and ready to move forward with the execution of its comprehensive business plan. Recently BrokerBank analyst Philip Wright, CFA initiated investment coverage of the company and has rated the company as a “speculative buy”. Wright praised the company for running on a lean basis by keeping salaries reasonable and office overhead costs extremely low.

The share structure of the stock is also attractive with only 7,929,246 shares of common stock outstanding as of last month. PuraMed is also a fully reporting company, meaning the company must be audited by a PCAOB registered public accounting firm and must comply with the requirements of Sarbanes-Oxley. These requirements allow for greater transparency and the ability to attract a larger investor audience, subsequently enhancing shareholder value and providing greater access to capital for further growth.

With a management team bringing more than 80 years of combined industry experience, a product line addressing major healthcare needs with many competitive advantages, and a well thought-out business plan, this company is well on its way to success in the multi-billion dollar OTC medicine market. Continue to watch this company as it strives to dramatically improve the quality of life for millions of Americans.

About the Company

PuraMed was established to capture two unique opportunities. The first is to build a substantial and profitable business, rapidly, beginning with three products developed by its founders: LipiGesic™ M (for acute relief of migraine headaches), LipiGesic™ H(for acute relief of tension headaches) and PuraMed™ PM (for insomnia). Each of these is effective and addresses a very large OTC consumer market, collectively well over $2 billion in the U.S. Each product will be unique in its class .

Upcoming Events ..2 Presentation in 2010

http://www.investorawareness.com/default.asp

Upcoming Events

PuraMed BioScience Financial Luncheon Presentation
- Tuesday, January 19, 2010
- 12:00 pm (event details)

PuraMed BioScience Financial Luncheon Presentation
- Wednesday, January 20, 2010
- 12:00 pm (event details)

The recent pullback in the stock price presents an attractive entry point ahead of several catalysts in 2010 !

GLTA


Puramed (PMBS.OB)

Market Cap: 7,7 Mio$
Price: 0,65 $

Shares Out : 11,99 M (8,6 M Shares held by Insider)
Float : 2,6 Million

Why Puramed Bioscience Inc. (PMBS.OB) Should Be On Your Radar

PuraMed Bioscience, Inc. is a pharmaceutical company focused on developing and marketing a line of new, non-prescription medicines. These products target major consumer health needs, including the treatment of headaches, insomnia, and general pain. The company aims launch its first retail products within six months, and then leverage that success to become a leader in the Over-the-Counter (OTC) medicine marketplace.

Although PuraMed Bioscience is entering into a competitive market, the company’s products promise to bring innovation to the industry, allowing for faster absorption into the blood stream, greater effectiveness, fewer side effects, and lower dosage requirements. The first three products the company plans to introduce include: LipiGesic M™ (for acute relief of migraine headaches), LipiGesic H™ (for acute relief of tension headaches) and LipiGesic PM™ (for insomnia).

PuraMed is already sufficiently funded via private funding and ready to move forward with the execution of its comprehensive business plan. Recently BrokerBank analyst Philip Wright, CFA initiated investment coverage of the company and has rated the company as a “speculative buy”. Wright praised the company for running on a lean basis by keeping salaries reasonable and office overhead costs extremely low.

The share structure of the stock is also attractive with only 7,929,246 shares of common stock outstanding as of last month. PuraMed is also a fully reporting company, meaning the company must be audited by a PCAOB registered public accounting firm and must comply with the requirements of Sarbanes-Oxley. These requirements allow for greater transparency and the ability to attract a larger investor audience, subsequently enhancing shareholder value and providing greater access to capital for further growth.

With a management team bringing more than 80 years of combined industry experience, a product line addressing major healthcare needs with many competitive advantages, and a well thought-out business plan, this company is well on its way to success in the multi-billion dollar OTC medicine market. Continue to watch this company as it strives to dramatically improve the quality of life for millions of Americans.

About the Company

PuraMed was established to capture two unique opportunities. The first is to build a substantial and profitable business, rapidly, beginning with three products developed by its founders: LipiGesic™ M (for acute relief of migraine headaches), LipiGesic™ H(for acute relief of tension headaches) and PuraMed™ PM (for insomnia). Each of these is effective and addresses a very large OTC consumer market, collectively well over $2 billion in the U.S. Each product will be unique in its class .

Tremendous upside Potential

IGXT.OB

Market Cap : 18 Mio$

Filed NDA with U.S. Food and Drug Administration (FDA) - on April 3, 2009 the Company and Cary Pharmaceuticals filed a New Drug Application (NDA) under CFR 21 paragraph 505(b)(2) for the CPI-300 antidepressant. CPI-300 is a new strength of a leading antidepressant that will provide a more convenient dosing option to patients with major depressive disorder ("MDD").

The NDA has been formally accepted by the FDA for standard review. Pursuant to Prescription Drug User Fee Act (PDUFA) guidelines, IntelGenx expects the FDA will complete its review or otherwise respond to the NDA by February 6, 2010.

Get in before its too late !!!!

Good news coming soon ..

Great opportunity

PDUFA Date 6 Feb 2010= BUY NOW

If you do your homework, you will clearly see that this stock will rise rapidly as soon as it gets noticed. Don't miss the boat !

IGXT.OB

Market Cap : 18 Million US$
Price : 0,56

Shares Out : 33 M

Great Pipeline
http://www.intelgenx.com/products/pipeline.html

IntelGenx Corp. Announces FDA Acceptance for Filing of NDA for CPI-300 Antidepressant

On Tuesday June 23, 2009, 6:00 am EDT

IntelGenx Corp. (TSX-V: IGX)(OTC.BB: IGXT) ("IntelGenx") today announced that the New Drug Application filing for their antidepressant CPI-300 has been accepted by the U.S. Food and Drug Administration (FDA) for standard review. Pursuant to Prescription Drug User Fee Act (PDUFA) guidelines, IntelGenx expects the FDA will complete its review or otherwise respond to the NDA by February 6, 2010.

"Formal FDA acceptance of the NDA clears the path towards review and approval of CPI-300 within the timeframe expected" said Dr. Horst G. Zerbe, President and Chief Executive Officer of IntelGenx. "We are especially pleased to note that the FDA has confirmed that our NDA was sufficiently complete to permit a substantive review. As CPI-300 represents our very first NDA, this is not only a testament to the expertise of our staff but also to the strength of our partners."

Load up the truck .Rally will start soon !!!!!

IGXT.OB

Market Cap : 18 Million US$
Price : 0,56

Shares Out : 33 M

Great Pipeline
http://www.intelgenx.com/products/pipeline.html

IntelGenx Corp. Announces FDA Acceptance for Filing of NDA for CPI-300 Antidepressant

On Tuesday June 23, 2009, 6:00 am EDT

IntelGenx Corp. (TSX-V: IGX)(OTC.BB: IGXT) ("IntelGenx") today announced that the New Drug Application filing for their antidepressant CPI-300 has been accepted by the U.S. Food and Drug Administration (FDA) for standard review. Pursuant to Prescription Drug User Fee Act (PDUFA) guidelines, IntelGenx expects the FDA will complete its review or otherwise respond to the NDA by February 6, 2010.

"Formal FDA acceptance of the NDA clears the path towards review and approval of CPI-300 within the timeframe expected" said Dr. Horst G. Zerbe, President and Chief Executive Officer of IntelGenx. "We are especially pleased to note that the FDA has confirmed that our NDA was sufficiently complete to permit a substantive review. As CPI-300 represents our very first NDA, this is not only a testament to the expertise of our staff but also to the strength of our partners."

Time to Buy !!!!!!!!!!!!!!!!1

Puramed (PMBS.OB)

Market Cap: 10,5 Mio$
Price: 0,85 $

Shares Out : 11,99 M ( 8,6 M Shares held by Insider)
Float : 2,6 Million


PuraMed Bioscience, Inc. (PMBS.OB) Targets Two Market Opportunities


PuraMed Bioscience, Inc., a non-prescription pharmaceutical company, believes it has identified huge and largely untapped market opportunities, and has laid out a solid plan to capture them. The company, based in Schofield, Wisconsin, was established with two specific goals in mind, representing these two OTC (over-the-counter) product opportunities.

The first objective is to rapidly build a substantial and profitable business based upon three OTC products already developed by the company founders. The products, designed for headache and insomnia relief, are each unique in their own class, and collectively target a $2 billion American market.

LipiGesic MTM is a proprietary formulation created for the acute relief of migraine headaches within minutes. LipiGesic HTM is designed to dramatically increase the speed and levels of relief of tension headaches, effective at low doses and with the fewest potential side effects. LipiGesic PMTM is a new class of OTC sleep aid containing a proprietary blend of ingredients for the quick and natural relief of insomnia.

The second, longer term objective is to establish a leadership position in the highly fragmented OTC natural and alternative health remedy market by introducing a new kind of product line. By applying hard science to natural products, PuraMed believes it can deliver products providing better performance while having fewer side effects.

The company also believes their products will benefit from the kind of effective opportunity identification and marketing that is largely absent in the natural OTC market. Promising research in the field often goes overlooked for years by large pharmaceutical companies. Through the effective use of clinical trials in conjunction with carefully timed and aggressive marketing, PuraMed is convinced that it can better reach a major part of the OTC market.

The two founders of PuraMed, Russ Mitchell and Jim Higgins, both have extensive experience in the successful sale and distribution of new health products, with novel strategies that have proven highly effective over multiple applications. Through the use of outside production and other third party resources, they plan to rapidly build their position, and consider marketing to be key to the new company’s success.


About the Company

PuraMed was established to capture two unique opportunities. The first is to build a substantial and profitable business, rapidly, beginning with three products developed by its founders: LipiGesic™ M (for acute relief of migraine headaches), LipiGesic™ H(for acute relief of tension headaches) and PuraMed™ PM (for insomnia). Each of these is effective and addresses a very large OTC consumer market, collectively well over $2 billion in the U.S. Each product will be unique in its class .

Time to Buy !!!!!!


Puramed (PMBS.OB)

Market Cap: 10,5 Mio$
Price: 0,85 $

Shares Out : 11,99 M ( 8,6 M Shares held by Insider)
Float : 2,6 Million


PuraMed Bioscience, Inc. (PMBS.OB) Targets Two Market Opportunities


PuraMed Bioscience, Inc., a non-prescription pharmaceutical company, believes it has identified huge and largely untapped market opportunities, and has laid out a solid plan to capture them. The company, based in Schofield, Wisconsin, was established with two specific goals in mind, representing these two OTC (over-the-counter) product opportunities.

The first objective is to rapidly build a substantial and profitable business based upon three OTC products already developed by the company founders. The products, designed for headache and insomnia relief, are each unique in their own class, and collectively target a $2 billion American market.

LipiGesic MTM is a proprietary formulation created for the acute relief of migraine headaches within minutes. LipiGesic HTM is designed to dramatically increase the speed and levels of relief of tension headaches, effective at low doses and with the fewest potential side effects. LipiGesic PMTM is a new class of OTC sleep aid containing a proprietary blend of ingredients for the quick and natural relief of insomnia.

The second, longer term objective is to establish a leadership position in the highly fragmented OTC natural and alternative health remedy market by introducing a new kind of product line. By applying hard science to natural products, PuraMed believes it can deliver products providing better performance while having fewer side effects.

The company also believes their products will benefit from the kind of effective opportunity identification and marketing that is largely absent in the natural OTC market. Promising research in the field often goes overlooked for years by large pharmaceutical companies. Through the effective use of clinical trials in conjunction with carefully timed and aggressive marketing, PuraMed is convinced that it can better reach a major part of the OTC market.

The two founders of PuraMed, Russ Mitchell and Jim Higgins, both have extensive experience in the successful sale and distribution of new health products, with novel strategies that have proven highly effective over multiple applications. Through the use of outside production and other third party resources, they plan to rapidly build their position, and consider marketing to be key to the new company’s success.


About the Company

PuraMed was established to capture two unique opportunities. The first is to build a substantial and profitable business, rapidly, beginning with three products developed by its founders: LipiGesic™ M (for acute relief of migraine headaches), LipiGesic™ H(for acute relief of tension headaches) and PuraMed™ PM (for insomnia). Each of these is effective and addresses a very large OTC consumer market, collectively well over $2 billion in the U.S. Each product will be unique in its class .

Great buying Opprtunity ...

Puramed (PMBS.OB)

Market Cap: 11,9 Mio$
Price: 1 $

Shares Out : 11,99 M ( 8,6 M Shares held by Insider)
Float : 2,6 Million


PuraMed Bioscience, Inc. (PMBS.OB) Targets Two Market Opportunities


PuraMed Bioscience, Inc., a non-prescription pharmaceutical company, believes it has identified huge and largely untapped market opportunities, and has laid out a solid plan to capture them. The company, based in Schofield, Wisconsin, was established with two specific goals in mind, representing these two OTC (over-the-counter) product opportunities.

The first objective is to rapidly build a substantial and profitable business based upon three OTC products already developed by the company founders. The products, designed for headache and insomnia relief, are each unique in their own class, and collectively target a $2 billion American market.

LipiGesic MTM is a proprietary formulation created for the acute relief of migraine headaches within minutes. LipiGesic HTM is designed to dramatically increase the speed and levels of relief of tension headaches, effective at low doses and with the fewest potential side effects. LipiGesic PMTM is a new class of OTC sleep aid containing a proprietary blend of ingredients for the quick and natural relief of insomnia.

The second, longer term objective is to establish a leadership position in the highly fragmented OTC natural and alternative health remedy market by introducing a new kind of product line. By applying hard science to natural products, PuraMed believes it can deliver products providing better performance while having fewer side effects.

The company also believes their products will benefit from the kind of effective opportunity identification and marketing that is largely absent in the natural OTC market. Promising research in the field often goes overlooked for years by large pharmaceutical companies. Through the effective use of clinical trials in conjunction with carefully timed and aggressive marketing, PuraMed is convinced that it can better reach a major part of the OTC market.

The two founders of PuraMed, Russ Mitchell and Jim Higgins, both have extensive experience in the successful sale and distribution of new health products, with novel strategies that have proven highly effective over multiple applications. Through the use of outside production and other third party resources, they plan to rapidly build their position, and consider marketing to be key to the new company’s success.


About the Company

PuraMed was established to capture two unique opportunities. The first is to build a substantial and profitable business, rapidly, beginning with three products developed by its founders: LipiGesic™ M (for acute relief of migraine headaches), LipiGesic™ H(for acute relief of tension headaches) and PuraMed™ PM (for insomnia). Each of these is effective and addresses a very large OTC consumer market, collectively well over $2 billion in the U.S. Each product will be unique in its class .

Another great buying Opportunity...

Puramed (PMBS.OB)

Market Cap: 11,9 Mio$
Price: 1 $

Shares Out : 11,99 M ( 8,6 M Shares held by Insider)
Float : 2,6 Million


PuraMed Bioscience, Inc. (PMBS.OB) Targets Two Market Opportunities


PuraMed Bioscience, Inc., a non-prescription pharmaceutical company, believes it has identified huge and largely untapped market opportunities, and has laid out a solid plan to capture them. The company, based in Schofield, Wisconsin, was established with two specific goals in mind, representing these two OTC (over-the-counter) product opportunities.

The first objective is to rapidly build a substantial and profitable business based upon three OTC products already developed by the company founders. The products, designed for headache and insomnia relief, are each unique in their own class, and collectively target a $2 billion American market.

LipiGesic MTM is a proprietary formulation created for the acute relief of migraine headaches within minutes. LipiGesic HTM is designed to dramatically increase the speed and levels of relief of tension headaches, effective at low doses and with the fewest potential side effects. LipiGesic PMTM is a new class of OTC sleep aid containing a proprietary blend of ingredients for the quick and natural relief of insomnia.

The second, longer term objective is to establish a leadership position in the highly fragmented OTC natural and alternative health remedy market by introducing a new kind of product line. By applying hard science to natural products, PuraMed believes it can deliver products providing better performance while having fewer side effects.

The company also believes their products will benefit from the kind of effective opportunity identification and marketing that is largely absent in the natural OTC market. Promising research in the field often goes overlooked for years by large pharmaceutical companies. Through the effective use of clinical trials in conjunction with carefully timed and aggressive marketing, PuraMed is convinced that it can better reach a major part of the OTC market.

The two founders of PuraMed, Russ Mitchell and Jim Higgins, both have extensive experience in the successful sale and distribution of new health products, with novel strategies that have proven highly effective over multiple applications. Through the use of outside production and other third party resources, they plan to rapidly build their position, and consider marketing to be key to the new company’s success.


About the Company

PuraMed was established to capture two unique opportunities. The first is to build a substantial and profitable business, rapidly, beginning with three products developed by its founders: LipiGesic™ M (for acute relief of migraine headaches), LipiGesic™ H(for acute relief of tension headaches) and PuraMed™ PM (for insomnia). Each of these is effective and addresses a very large OTC consumer market, collectively well over $2 billion in the U.S. Each product will be unique in its class .

CPEX hits new 52W High ....

Stock recommendation: Senetek PLC (sntky.ob)



We believe this stock is great buy at this very low price, and has lots of potential for a large upwards move in stock price in the range $3-10 in 2010 (250%-700%)

Senetek Fact Sheet

This is a very undervalued stock which has been living a quiet life on Nasdaq.

As of today (1. November 2009) it is priced at 1.3, which is less than the book value of the company!

Senetek has $12 million in cash and no debt! With about 8.5 million shares, it gives a P/B ratio of 12/8.5=1.41

Senetek PLC has a very valuable product and patent portfolio, from which it could gain hugh rises in profits over the next 1-5 years.
The company operates in two segments,

Skincare and Pharmaceutical:

Skincare

The Skincare segment offers Pyratine-6, a second generation cytokinin for the treatment of aging skin;
Pyratine XR for the visible signs and symptoms associated with various conditions, such as rosacea, eczema, contact dermatitis, and menopause;
(These have already been launched in 2009)

4HBAP, an aromatic cytokinin for the treatment of photodamaged skin and its effect on the reduction of erythema; and
(To marked in 1Q 2010)

Kinetin, a first generation cytokinin that is a plant growth factor, which retards senescence of plants and delays age-related changes in cultured human skin cells.
(Sold rights to Kinetin to VALEANT PHARMA which has had a hugh succes with it in the product line Kinerase)

Pharmaceutical:
The Pharmaceutical segment offers Invicorp, an intracavernous injection therapy for the treatment of male erectile dysfunction;
In has been approve for sale in Denmark, and partly in the UK. Pending PDA approval in US

Reliaject, an autoinjector system; and diagnostic monoclonal antibodies that are used in Alzheimer’s and other disease research.

Research
The company has research and collaboration agreements with the Institute of Experimental Botany in Prague, the Czech Republic for the research on plant physiology, genetics, and biotechnology;
Institute of Bioorganic Chemistry of the Polish Academy of Sciences in Poznan, Poland for the rights to three compounds for the treatment of skin aging, and technology used for the treatment of brain tumors using interference RNA; and PROTEOMAGE, the European integrated project on healthy aging.

It operates primarily in the United States, the United Kingdom, and Denmark. Senetek PLC was founded in 1983 and is headquartered in Napa, California.


Why is Senetek a great buy?

No matter which if the strategies below Senetek chooses in 2009 - 2010, it will push the price of the stock to a much higher level:

* It keeps it independency and let its sales grow organically. (likelihood 25%) (slower but steady rise in the share price in 2010, price $2-5 )
* It may sell of the Invicorp and Reliaject products and focus on the skincare sales, (likelihood 25%) (jump in price, and then slower but steady rise in the share price in 2010, a jump to $3-4 then move steadily to $6-7)
* May want merge, be bought by a larger skin-care company to better utilize sales channels, marketing etc. (likelihood 50%)(Large jump in price, $6-10)


and

* It has a shareholder approved share buy-back plan put in to place, which may start at any time.
* Senetek will move listing to a larger exchange in the future, this alone will boost the stock price
* The CEO has a large amount of shares and options and has very strong incentives to move the stock price to a much higher level

Stock recommendation: Senetek PLC (sntky.ob)



We believe this stock is great buy at this very low price, and has lots of potential for a large upwards move in stock price in the range $3-10 in 2010 (250%-700%)

Senetek Fact Sheet

This is a very undervalued stock which has been living a quiet life on Nasdaq.

As of today (1. November 2009) it is priced at 1.3, which is less than the book value of the company!

Senetek has $12 million in cash and no debt! With about 8.5 million shares, it gives a P/B ratio of 12/8.5=1.41

Senetek PLC has a very valuable product and patent portfolio, from which it could gain hugh rises in profits over the next 1-5 years.
The company operates in two segments,

Skincare and Pharmaceutical:

Skincare

The Skincare segment offers Pyratine-6, a second generation cytokinin for the treatment of aging skin;
Pyratine XR for the visible signs and symptoms associated with various conditions, such as rosacea, eczema, contact dermatitis, and menopause;
(These have already been launched in 2009)

4HBAP, an aromatic cytokinin for the treatment of photodamaged skin and its effect on the reduction of erythema; and
(To marked in 1Q 2010)

Kinetin, a first generation cytokinin that is a plant growth factor, which retards senescence of plants and delays age-related changes in cultured human skin cells.
(Sold rights to Kinetin to VALEANT PHARMA which has had a hugh succes with it in the product line Kinerase)

Pharmaceutical:
The Pharmaceutical segment offers Invicorp, an intracavernous injection therapy for the treatment of male erectile dysfunction;
In has been approve for sale in Denmark, and partly in the UK. Pending PDA approval in US

Reliaject, an autoinjector system; and diagnostic monoclonal antibodies that are used in Alzheimer’s and other disease research.

Research
The company has research and collaboration agreements with the Institute of Experimental Botany in Prague, the Czech Republic for the research on plant physiology, genetics, and biotechnology;
Institute of Bioorganic Chemistry of the Polish Academy of Sciences in Poznan, Poland for the rights to three compounds for the treatment of skin aging, and technology used for the treatment of brain tumors using interference RNA; and PROTEOMAGE, the European integrated project on healthy aging.

It operates primarily in the United States, the United Kingdom, and Denmark. Senetek PLC was founded in 1983 and is headquartered in Napa, California.


Why is Senetek a great buy?

No matter which if the strategies below Senetek chooses in 2009 - 2010, it will push the price of the stock to a much higher level:

* It keeps it independency and let its sales grow organically. (likelihood 25%) (slower but steady rise in the share price in 2010, price $2-5 )
* It may sell of the Invicorp and Reliaject products and focus on the skincare sales, (likelihood 25%) (jump in price, and then slower but steady rise in the share price in 2010, a jump to $3-4 then move steadily to $6-7)
* May want merge, be bought by a larger skin-care company to better utilize sales channels, marketing etc. (likelihood 50%)(Large jump in price, $6-10)


and

* It has a shareholder approved share buy-back plan put in to place, which may start at any time.
* Senetek will move listing to a larger exchange in the future, this alone will boost the stock price
* The CEO has a large amount of shares and options and has very strong incentives to move the stock price to a much higher level

Bullish Chart !!!!!!!!!

Get on board before the stock gets discovered .Please do your own DD !!! GLTA

New Partner Deal soon = 40-50$ Tgt within 6 Months !!!!

Cpex Pharma (CPEX)

Market Cap : 27,5 Mio$
Cash : 14,8 Mio$
Price : 10,70 $

Shares Out : 2,53 M


Pipeline
http://www.cpexpharm.com/pipeline.htm


Third-Quarter Highlights

For the third quarter of 2009 compared to the third quarter of 2008;

* Revenues increased 26% to $5.0 million from $3.9 million.
* Operating expenses increased 17% to $5.8 million from $5.0 million.
* Net loss was $872,000, or $0.34 per share, compared to $1.0 million, or $0.43 per share.

The growth in revenues for the third quarter of 2009 was due to increased royalties on sales of Testim®. This growth is due to a reported 17% increase in prescriptions for Testim during the third quarter of 2009 compared to the same period in 2008. Operating expenses in the third quarter of 2009 increased $853,000, primarily due to clinical trial expenses associated with CPEX’s ongoing NasulinTM clinical program and legal costs associated with its on-going litigation with Upsher-Smith Laboratories regarding Testim. These increases were partially offset by a decrease in share-based compensation expense. Operating expenses for the three months ended September 30, 2008 include a $1.2 million non-cash charge resulting from the modification of equity awards associated with the spin-off from Bentley.

Business Update

Ongoing Clinical Trials: CPEX’s intranasal insulin product candidate for the treatment of hyperglycemia in patients with Type 1 and Type 2 diabetes, Nasulin, is continuing clinical trials evaluating the safety and efficacy profile of the product. CPEX has completed screening activities in a Phase 2a study designed to assess the efficacy and safety of Nasulin versus placebo over a 6-week treatment period. This study is being conducted at multiple centers in the U.S. Prior trials in patients with Type 1 or 2 diabetes, as well as in healthy volunteers, have indicated that Nasulin appears to have an ultra-rapid time/action profile which has the potential to mimic more closely the body’s natural insulin response to meals.

Partnering Update: Following the completion of an End-of-Phase-2 meeting earlier this year, Serenity Pharmaceuticals, CPEX’s licensing and development partner, recently began recruiting patients in multiple Phase 3 clinical trials with their undisclosed urology drug delivered using CPEX’s intranasal technology for the treatment of nocturia. These randomized, double blind, placebo controlled studies are being conducted at multiple sites in the United States.

New Patents Issued: On October 27, 2009 the United States Patent and Trademark Office issued six additional patents that expand the scope and claims of CPEX’s original patent covering Testim®, 1% testosterone gel. Testim® is marketed by Auxilium under license from CPEX. The new patents will expire in April 2023 and are listed in Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book), published by the U.S. Food and Drug Administration.

Management Comments

“We are pleased about the recent completion of screening activities in our current Phase 2a study and the continued progress of our Nasulin clinical program. We look forward to presenting data from our earlier trials at the Ninth Annual Diabetes Technology Meeting taking place this week in San Francisco” stated John A. Sedor, CPEX President and Chief Executive Officer. “We are also encouraged by Serenity’s advancement of their compound for the treatment of nocturia into Phase 3 studies. This drug addresses a large urology indication with few treatment options. This is an exciting opportunity for CPEX and Serenity and we look forward to updating you on the future of this program .

Where Potential is noticed !!!!!!!

Interview with CEO
http://www.emergingissuer.com/index.php?Itemid=27&id=93&option=com_content&task=view

Where Potential is noticed !!!!!!!

Interview with CEO
http://www.emergingissuer.com/index.php?Itemid=27&id=93&option=com_content&task=view

CPEX is on the move

still very cheap ............

Cpex Pharma (CPEX)

Market Cap : 24,5 Mio$
Cash : 14,8 Mio$
Price : 9,50 $

Shares Out : 2,53 M


Pipeline
http://www.cpexpharm.com/pipeline.htm


Third-Quarter Highlights

For the third quarter of 2009 compared to the third quarter of 2008;

* Revenues increased 26% to $5.0 million from $3.9 million.
* Operating expenses increased 17% to $5.8 million from $5.0 million.
* Net loss was $872,000, or $0.34 per share, compared to $1.0 million, or $0.43 per share.

The growth in revenues for the third quarter of 2009 was due to increased royalties on sales of Testim®. This growth is due to a reported 17% increase in prescriptions for Testim during the third quarter of 2009 compared to the same period in 2008. Operating expenses in the third quarter of 2009 increased $853,000, primarily due to clinical trial expenses associated with CPEX’s ongoing NasulinTM clinical program and legal costs associated with its on-going litigation with Upsher-Smith Laboratories regarding Testim. These increases were partially offset by a decrease in share-based compensation expense. Operating expenses for the three months ended September 30, 2008 include a $1.2 million non-cash charge resulting from the modification of equity awards associated with the spin-off from Bentley.

Business Update

Ongoing Clinical Trials: CPEX’s intranasal insulin product candidate for the treatment of hyperglycemia in patients with Type 1 and Type 2 diabetes, Nasulin, is continuing clinical trials evaluating the safety and efficacy profile of the product. CPEX has completed screening activities in a Phase 2a study designed to assess the efficacy and safety of Nasulin versus placebo over a 6-week treatment period. This study is being conducted at multiple centers in the U.S. Prior trials in patients with Type 1 or 2 diabetes, as well as in healthy volunteers, have indicated that Nasulin appears to have an ultra-rapid time/action profile which has the potential to mimic more closely the body’s natural insulin response to meals.

Partnering Update: Following the completion of an End-of-Phase-2 meeting earlier this year, Serenity Pharmaceuticals, CPEX’s licensing and development partner, recently began recruiting patients in multiple Phase 3 clinical trials with their undisclosed urology drug delivered using CPEX’s intranasal technology for the treatment of nocturia. These randomized, double blind, placebo controlled studies are being conducted at multiple sites in the United States.

New Patents Issued: On October 27, 2009 the United States Patent and Trademark Office issued six additional patents that expand the scope and claims of CPEX’s original patent covering Testim®, 1% testosterone gel. Testim® is marketed by Auxilium under license from CPEX. The new patents will expire in April 2023 and are listed in Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book), published by the U.S. Food and Drug Administration.

Management Comments

“We are pleased about the recent completion of screening activities in our current Phase 2a study and the continued progress of our Nasulin clinical program. We look forward to presenting data from our earlier trials at the Ninth Annual Diabetes Technology Meeting taking place this week in San Francisco” stated John A. Sedor, CPEX President and Chief Executive Officer. “We are also encouraged by Serenity’s advancement of their compound for the treatment of nocturia into Phase 3 studies. This drug addresses a large urology indication with few treatment options. This is an exciting opportunity for CPEX and Serenity and we look forward to updating you on the future of this program.”

Break Out is Coming Soon

Strong buy at this price ..

Get in before its too late !!!!

www.lipigesic.com

LIPIGESIC (MIGRAINE) LAUNCH THIS WEEK = 10 BAGGER EASILY !!!


Puramed (PMBS.OB)

Market Cap: 20 Mio$
Price: 1,74 $

Shares Out : 11,99 M ( 8,6 M Shares held by Insider)
Float : 2,6 Million


PuraMed Bioscience, Inc. (PMBS.OB) Targets Two Market Opportunities


PuraMed Bioscience, Inc., a non-prescription pharmaceutical company, believes it has identified huge and largely untapped market opportunities, and has laid out a solid plan to capture them. The company, based in Schofield, Wisconsin, was established with two specific goals in mind, representing these two OTC (over-the-counter) product opportunities.

The first objective is to rapidly build a substantial and profitable business based upon three OTC products already developed by the company founders. The products, designed for headache and insomnia relief, are each unique in their own class, and collectively target a $2 billion American market.

LipiGesic MTM is a proprietary formulation created for the acute relief of migraine headaches within minutes. LipiGesic HTM is designed to dramatically increase the speed and levels of relief of tension headaches, effective at low doses and with the fewest potential side effects. LipiGesic PMTM is a new class of OTC sleep aid containing a proprietary blend of ingredients for the quick and natural relief of insomnia.

The second, longer term objective is to establish a leadership position in the highly fragmented OTC natural and alternative health remedy market by introducing a new kind of product line. By applying hard science to natural products, PuraMed believes it can deliver products providing better performance while having fewer side effects.

The company also believes their products will benefit from the kind of effective opportunity identification and marketing that is largely absent in the natural OTC market. Promising research in the field often goes overlooked for years by large pharmaceutical companies. Through the effective use of clinical trials in conjunction with carefully timed and aggressive marketing, PuraMed is convinced that it can better reach a major part of the OTC market.

The two founders of PuraMed, Russ Mitchell and Jim Higgins, both have extensive experience in the successful sale and distribution of new health products, with novel strategies that have proven highly effective over multiple applications. Through the use of outside production and other third party resources, they plan to rapidly build their position, and consider marketing to be key to the new company’s success.


About the Company

PuraMed was established to capture two unique opportunities. The first is to build a substantial and profitable business, rapidly, beginning with three products developed by its founders: LipiGesic™ M (for acute relief of migraine headaches), LipiGesic™ H(for acute relief of tension headaches) and PuraMed™ PM (for insomnia). Each of these is effective and addresses a very large OTC consumer market, collectively well over $2 billion in the U.S. Each product will be unique in its class .

STRONG BUY


www.lipigesic.com

LIPIGESIC (MIGRAINE) LAUNCH THIS WEEK = 10 BAGGER EASILY !!!


Puramed (PMBS.OB)

Market Cap: 20 Mio$
Price: 1,74 $

Shares Out : 11,99 M ( 8,6 M Shares held by Insider)
Float : 2,6 Million


PuraMed Bioscience, Inc. (PMBS.OB) Targets Two Market Opportunities


PuraMed Bioscience, Inc., a non-prescription pharmaceutical company, believes it has identified huge and largely untapped market opportunities, and has laid out a solid plan to capture them. The company, based in Schofield, Wisconsin, was established with two specific goals in mind, representing these two OTC (over-the-counter) product opportunities.

The first objective is to rapidly build a substantial and profitable business based upon three OTC products already developed by the company founders. The products, designed for headache and insomnia relief, are each unique in their own class, and collectively target a $2 billion American market.

LipiGesic MTM is a proprietary formulation created for the acute relief of migraine headaches within minutes. LipiGesic HTM is designed to dramatically increase the speed and levels of relief of tension headaches, effective at low doses and with the fewest potential side effects. LipiGesic PMTM is a new class of OTC sleep aid containing a proprietary blend of ingredients for the quick and natural relief of insomnia.

The second, longer term objective is to establish a leadership position in the highly fragmented OTC natural and alternative health remedy market by introducing a new kind of product line. By applying hard science to natural products, PuraMed believes it can deliver products providing better performance while having fewer side effects.

The company also believes their products will benefit from the kind of effective opportunity identification and marketing that is largely absent in the natural OTC market. Promising research in the field often goes overlooked for years by large pharmaceutical companies. Through the effective use of clinical trials in conjunction with carefully timed and aggressive marketing, PuraMed is convinced that it can better reach a major part of the OTC market.

The two founders of PuraMed, Russ Mitchell and Jim Higgins, both have extensive experience in the successful sale and distribution of new health products, with novel strategies that have proven highly effective over multiple applications. Through the use of outside production and other third party resources, they plan to rapidly build their position, and consider marketing to be key to the new company’s success.


About the Company

PuraMed was established to capture two unique opportunities. The first is to build a substantial and profitable business, rapidly, beginning with three products developed by its founders: LipiGesic™ M (for acute relief of migraine headaches), LipiGesic™ H(for acute relief of tension headaches) and PuraMed™ PM (for insomnia). Each of these is effective and addresses a very large OTC consumer market, collectively well over $2 billion in the U.S. Each product will be unique in its class .

Undiscovered Stock with huge upside Potential .GLTA

Intelgenx ( IGXT.OB )

Marketcap 15 M$
Price: 0,60 $


Great Pipeline
http://intelgenx.com/products/pipeline.html


Developments Intelgenx announced that the FDA has finished its preliminary review and accepted Intelgenx’s NDA filing for CPI-300, a 450mg extended release Bupropion tablet. Impact Positive. Intelgenx is keeping to its timeline and we should see the tablet approved by Q4/09 and on the market by Q1/10. Comments The FDA has begun its full review of Intelgenx’s 450mg Bupropion tablet, which is excellent news for the company and maintains their timeline.

BIG NEWS WITHIN 1 WEEK...

STILL VERY CHEAP !

Still a great buying Opportunity !!!

PuraMed Bioscience, Inc. (PMBS.OB) Targets Two Market Opportunities


PuraMed Bioscience, Inc., a non-prescription pharmaceutical company, believes it has identified huge and largely untapped market opportunities, and has laid out a solid plan to capture them. The company, based in Schofield, Wisconsin, was established with two specific goals in mind, representing these two OTC (over-the-counter) product opportunities.

The first objective is to rapidly build a substantial and profitable business based upon three OTC products already developed by the company founders. The products, designed for headache and insomnia relief, are each unique in their own class, and collectively target a $2 billion American market.

LipiGesic MTM is a proprietary formulation created for the acute relief of migraine headaches within minutes. LipiGesic HTM is designed to dramatically increase the speed and levels of relief of tension headaches, effective at low doses and with the fewest potential side effects. LipiGesic PMTM is a new class of OTC sleep aid containing a proprietary blend of ingredients for the quick and natural relief of insomnia.

The second, longer term objective is to establish a leadership position in the highly fragmented OTC natural and alternative health remedy market by introducing a new kind of product line. By applying hard science to natural products, PuraMed believes it can deliver products providing better performance while having fewer side effects.

The company also believes their products will benefit from the kind of effective opportunity identification and marketing that is largely absent in the natural OTC market. Promising research in the field often goes overlooked for years by large pharmaceutical companies. Through the effective use of clinical trials in conjunction with carefully timed and aggressive marketing, PuraMed is convinced that it can better reach a major part of the OTC market.

The two founders of PuraMed, Russ Mitchell and Jim Higgins, both have extensive experience in the successful sale and distribution of new health products, with novel strategies that have proven highly effective over multiple applications. Through the use of outside production and other third party resources, they plan to rapidly build their position, and consider marketing to be key to the new company’s success.

Big Explode will happen any day now !!!!!

PuraMed Bioscience, Inc. (PMBS.OB) Targets Two Market Opportunities


PuraMed Bioscience, Inc., a non-prescription pharmaceutical company, believes it has identified huge and largely untapped market opportunities, and has laid out a solid plan to capture them. The company, based in Schofield, Wisconsin, was established with two specific goals in mind, representing these two OTC (over-the-counter) product opportunities.

The first objective is to rapidly build a substantial and profitable business based upon three OTC products already developed by the company founders. The products, designed for headache and insomnia relief, are each unique in their own class, and collectively target a $2 billion American market.

LipiGesic MTM is a proprietary formulation created for the acute relief of migraine headaches within minutes. LipiGesic HTM is designed to dramatically increase the speed and levels of relief of tension headaches, effective at low doses and with the fewest potential side effects. LipiGesic PMTM is a new class of OTC sleep aid containing a proprietary blend of ingredients for the quick and natural relief of insomnia.

The second, longer term objective is to establish a leadership position in the highly fragmented OTC natural and alternative health remedy market by introducing a new kind of product line. By applying hard science to natural products, PuraMed believes it can deliver products providing better performance while having fewer side effects.

The company also believes their products will benefit from the kind of effective opportunity identification and marketing that is largely absent in the natural OTC market. Promising research in the field often goes overlooked for years by large pharmaceutical companies. Through the effective use of clinical trials in conjunction with carefully timed and aggressive marketing, PuraMed is convinced that it can better reach a major part of the OTC market.

The two founders of PuraMed, Russ Mitchell and Jim Higgins, both have extensive experience in the successful sale and distribution of new health products, with novel strategies that have proven highly effective over multiple applications. Through the use of outside production and other third party resources, they plan to rapidly build their position, and consider marketing to be key to the new company’s success.

Market Cap 0f 23 M4 is a Joke !!!

Shares Out only 2,5 M

Fact Sheet:
http://www.cpexpharm.com/files/pdfs/fs/factsheet.pdf


Gabelli & Co. initiates coverage on CPEX Pharmaceuticals, Inc (Nasdaq: CPEX) with a Buy. Price target $17.


Zacks #1 Rank Additions for Thursday
Here are the stocks added to the Zacks #1 Rank ("strong buy") List today:

# 3PAR Inc (PAR - Snapshot Report)
# American Medical Systems Holdings Inc (AMMD - Analyst Report)
# Ameristar Casinos Inc (ASCA - Snapshot Report)
# Ashland Inc (ASH - Snapshot Report)
# Bank Mutual Corp (BKMU - Snapshot Report)
# BigBand Networks Inc (BBND - Snapshot Report)
# Capitol Federal Financial (CFFN - Snapshot Report)
# Central Garden & Pet Co (CENT - Analyst Report)
# CGI Group Inc (GIB - Snapshot Report)
# Conexant Systems Inc (CNXT - Snapshot Report)
# CPEX Pharmaceuticals Inc (CPEX)

BUY NOW OR PAY MORE LATER



Puramed (PMBS.OB)

Market Cap: 18 Mio$
Price: 1,51 $

Shares Out : 11,99 M (8,6 M Shares held by Insider)
Float : 2,6 Million

Why Puramed Bioscience Inc. (PMBS.OB) Should Be On Your Radar

PuraMed Bioscience, Inc. is a pharmaceutical company focused on developing and marketing a line of new, non-prescription medicines. These products target major consumer health needs, including the treatment of headaches, insomnia, and general pain. The company aims launch its first retail products within six months, and then leverage that success to become a leader in the Over-the-Counter (OTC) medicine marketplace.

Although PuraMed Bioscience is entering into a competitive market, the company’s products promise to bring innovation to the industry, allowing for faster absorption into the blood stream, greater effectiveness, fewer side effects, and lower dosage requirements. The first three products the company plans to introduce include: LipiGesic M™ (for acute relief of migraine headaches), LipiGesic H™ (for acute relief of tension headaches) and LipiGesic PM™ (for insomnia).

PuraMed is already sufficiently funded via private funding and ready to move forward with the execution of its comprehensive business plan. Recently BrokerBank analyst Philip Wright, CFA initiated investment coverage of the company and has rated the company as a “speculative buy”. Wright praised the company for running on a lean basis by keeping salaries reasonable and office overhead costs extremely low.

The share structure of the stock is also attractive with only 7,929,246 shares of common stock outstanding as of last month. PuraMed is also a fully reporting company, meaning the company must be audited by a PCAOB registered public accounting firm and must comply with the requirements of Sarbanes-Oxley. These requirements allow for greater transparency and the ability to attract a larger investor audience, subsequently enhancing shareholder value and providing greater access to capital for further growth.

With a management team bringing more than 80 years of combined industry experience, a product line addressing major healthcare needs with many competitive advantages, and a well thought-out business plan, this company is well on its way to success in the multi-billion dollar OTC medicine market. Continue to watch this company as it strives to dramatically improve the quality of life for millions of Americans.

About the Company

PuraMed was established to capture two unique opportunities. The first is to build a substantial and profitable business, rapidly, beginning with three products developed by its founders: LipiGesic™ M (for acute relief of migraine headaches), LipiGesic™ H(for acute relief of tension headaches) and PuraMed™ PM (for insomnia). Each of these is effective and addresses a very large OTC consumer market, collectively well over $2 billion in the U.S. Each product will be unique in its class .